To identify genetic variants influencing plasma lipid concentrations, we first used genotype imputation and meta-analysis to combine three genome-wide scans totaling 8,816 individuals and comprising 6,068 individuals specific to our study (1,874 individuals from the FUSION study of type 2 diabetes and 4,184 individuals from the SardiNIA study of aging-associated variables) and 2,758 individuals from the Diabetes Genetics Initiative, reported in a companion study in this issue. We subsequently examined promising signals in 11,569 additional individuals. Overall, we identify strongly associated variants in eleven loci previously implicated in lipid metabolism (ABCA1, the APOA5-APOA4-APOC3-APOA1 and APOE-APOC clusters, APOB, CETP, GCKR, LDLR, LPL, LIPC, LIPG and PCSK9) and also in several newly identified loci (near MVK-MMAB and GALNT2, with variants primarily associated with high-density lipoprotein (HDL) cholesterol; near SORT1, with variants primarily associated with low-density lipoprotein (LDL) cholesterol; near TRIB1, MLXIPL and ANGPTL3, with variants primarily associated with triglycerides; and a locus encompassing several genes near NCAN, with variants strongly associated with both triglycerides and LDL cholesterol). Notably, the 11 independent variants associated with increased LDL cholesterol concentrations in our study also showed increased frequency in a sample of coronary artery disease cases versus controls.
cholesterol are associated with increased risk of CAD, high concentrations of HDL cholesterol are associated with decreased risk of CAD. Specifically, it has been estimated that each 1% decrease in LDL cholesterol concentrations reduces the risk of coronary heart disease by B1% (ref. 5) , and each 1% increase in HDL cholesterol concentrations reduces the risk of coronary heart disease by B2% (ref. 6) . A recent meta-analysis of data on 150,000 individuals, including 3,000 with CAD-related deaths, shows that the two factors are independently associated with CAD risk 7 . There is evidence that a high concentration of triglycerides is an additional, independent risk factor for cardiovascular disease 8, 9 , although whether this association is causal is still under debate.
Smoking, diet and physical activity all have a role in determining individual lipid profiles. Still, family studies suggest that in many populations, about half of the variation in these traits is genetically determined 10, 11 , and it is clear that LDL cholesterol, HDL cholesterol and triglyceride concentrations are strongly influenced by the genetic constitution of each individual. Furthermore, genetic variants that increase LDL cholesterol concentrations-such as rare variants in the LDL receptor (LDLR) and apolipoprotein B (APOB) genes and common variants in the apolipoprotein E (APOE) gene-have also been associated with increased susceptibility to coronary heart disease 12 . Thus, the available evidence demonstrates not only that genetic variants account for a substantial fraction of individual variation in lipid concentrations, but also that lipid concentrations are associated with the risk of CAD.
Although several genes and genetic variants have been found that associate with individual variation in lipid concentrations, additional variants influencing these traits remain to be identified. As with other complex traits, identification of genes influencing lipid concentrations is likely to be much enhanced by large sample sizes. Thus, we decided to combine genome-wide association scan data from two of our studies, including 1,874 individuals from the FUSION study of type 2 diabetes 13 and 4,184 individuals from the SardiNIA study of agingassociated variables 10, 14 , with data on 2,758 individuals from the Diabetes Genetics Initiative 15, 16 . Here, we describe results of a combined analysis of the three genome-wide association scans involving a total of 8,816 individuals and our follow-up assessments of up to 11,569 individuals, which were done in order to verify common genetic variants associated with plasma concentrations of LDL cholesterol, HDL cholesterol and triglycerides. Our results identify 425 independent common variants associated with individual variation in lipid concentrations (each with P o 5 Â 10 À8 ). Some are located in previously implicated loci, indicating that our approach was valid, and others are found in loci where genetic variants have not been previously implicated in lipid metabolism. Our results also provide promising, albeit not definitive, evidence of association between several other common variants and lipid concentrations. In a companion manuscript, Kathiresan and colleagues from the Diabetes Genetics Initiative report results of their own follow-up genotyping of SNPs selected on the basis of our combined analysis of the three scans, their original analyses, and previously published reports. Their independent follow-up samples and genotyping further support the newly identified loci reported here.
RESULTS

Genome-wide association scans
To survey the genome for common variants associated with plasma concentrations of HDL cholesterol, LDL cholesterol and triglyceride concentrations, we conducted genome-wide association scans on two different populations. In one scan, after we excluded markers on the basis of quality-control filters (see Methods), we examined 304,581 SNPs with minor allele frequency (MAF) 41% from the Illumina HumanHap300 BeadChip and a GoldenGate panel designed to We then conducted a series of association analyses to relate the B2,261,000 genotyped and/or imputed SNPs with plasma Figure 1 Summary of genome-wide association scans. The figure summarizes combined genome-wide association scan results in the top 3 panels (plotted as -log 10 P value for HDL cholesterol, LDL cholesterol and triglycerides). Loci that were not followed up are in gray. Loci that were followed-up are in green (combined dataset yielded convincing evidence of association, P o 5 Â 10 À8 ), orange (combined dataset yielded promising evidence of association, P o 10 À5 ), or red (combined dataset did not suggest association, P 4 10 À5 ). The three panels in the bottom row display quantile-quantile plots for test statistics. The red line corresponds to all test statistics, the blue line corresponds to results after excluding statistics at replicated loci (in green, top panel), and the gray area corresponds to the 90% confidence region from a null distribution of P values (generated from 100 simulations).
concentrations of HDL cholesterol, LDL cholesterol and triglyceride concentrations. For each SNP, lipid concentrations were regressed onto allele counts in a regression model that also included gender, age and age 2 as covariates. For the FUSION sample, we analyzed T2D cases and controls separately, and added additional covariates accounting for birth province and study subset. For the DGI sample, we analyzed cases and controls together using an additional covariate to indicate diabetes status. For SNPs genotyped in the lab, allele counts were discrete (0, 1 or 2), whereas for SNPs genotyped in silico, allele counts were fractional (between 0.0 and 2.0, depending on the imputed number of copies of the allele for each individual; see Methods). To allow for relatedness in the FUSION and SardiNIA samples, we estimated regression coefficients in the context of a variance component model that modeled background polygenic effects 17 . As usual 20, 21 , modeling polygenic effects is important in the context of an association study such as this one, because ignoring relatedness among sampled individuals can lead to misleading P values and inflated false-positive rates. Figure 1 shows the results of a meta-analysis of the initial scans from all three studies, comprising a total of 8,816 participants. The genomic control 22 parameters for this meta-analysis were 1.04, 1.02 and 1.01 (for HDL cholesterol, LDL cholesterol and triglycerides, respectively), suggesting that population stratification and unmodeled relatedness had negligible impact on our association results. Stage 1 results indicate strong association with lipids for 18 loci where at least one SNP exceeds the arbitrary threshold of P o 5 Â 10 À7 ( Table 2) . Several loci previously implicated in lipid metabolism show strong evidence for association, including regions near CETP (strongest association at rs3764261, P o 10 À18 , HDL cholesterol concentration increase of 2.42 mg/dl per A allele), LPL (rs12678919, P o 10 À10 , 2.44 mg/dl increase per G allele), LIPC (rs10468017, P o 10 À10 , 1.76 mg/dl increase per T allele), ABCA1 (rs4149274, P B7.4 Â 10 À8 , 1.51 mg/dl increase per G allele) and LIPG (rs4939883, P B1.4 Â 10 À7 , 1.87 mg/dl increase per C allele) associated with HDL cholesterol concentrations; the APOE-APOC1-APOC4-APOC2 cluster (rs4420638, P o 10 À20 , 8.02 mg/dl increase per G allele), APOB (rs515135, P o 10 À13 , 6.08 mg/dl increase per C allele) and LDLR (rs6511720, P o 10 À9 , 8.03 mg/dl increase per C allele) associated with LDL cholesterol concentrations; and near the APOA5-APOA4-APOC3-APOA1 cluster (rs964184, P o 10 À15 , 18.12 mg/dl increase per G allele), GCKR (rs1260326, P o 10 À14 , 10.25 mg/dl increase per T allele) and LPL (rs6993414, P o 10 À12 , 14.20 mg/dl increase per A allele) associated with triglyceride concentrations. At several of these loci, the SNP showing strongest association was in linkage disequilibrium (LD) with previously identified variants (r 2 4 0.80) or had itself been previously reported to show association. However, at other loci-in particular, the regions near LIPC, LIPG, LDLR and APOB-strongly associated SNPs were in only weak LD with previously identified variants (r 2 o 0.30) and thus were likely to represent new signals (Supplementary Table 2 online). At the GCKR locus, the strongest observed association was with a coding SNP, consistent with the results of a recent detailed analysis of the region (S. Kathiresan and M. Orho-Melander, personal communication). In addition to SNPs in these known loci, several other SNPs showed strong association in our initial genome-wide analysis. For example, SNPs near the GRIN3A, GALNT2, CELSR2-PSRC1-SORT1, NCAN-SF4 and TRIB1 genes all had P values o5 Â 10 À7 for at least one of the three lipid traits in our initial analysis ( Table 2) . We observed association with distinct gene sets for each of the three traits, consistent with the modest degree of correlation between the traits (the correlation between HDL and LDL cholesterol was essentially zero in our samples, the correlation between HDL cholesterol and triglycerides was approximately -0.4 and the correlation between LDL cholesterol and triglycerides was 0.3 in the SardiNIA sample and 0.1 in FUSION).
Follow-up of initial findings
To further evaluate these and other promising findings from our initial scan, we examined a subset of SNPs in six additional cohorts of European ancestry, totaling 11,569 individuals ( Table 1) . These follow-up analyses were conducted in several stages. In a first round of follow-up analysis, SNPs included on the Affymetrix arrays (genotyped in SardiNIA and DGI) and imputed or genotyped in FUSION were selected for follow-up on the basis of a preliminary metaanalysis. We selected a total of 100 SNPs in this manner for examination in the ISIS 23 Fig. 1 and Supplementary Methods online). Table 3 provides a summary of the stage 2 results and a combined analysis of the data from both stage 1 and stage 2. The table includes the SNP with the strongest association signal at each locus and a selection of additional SNPs that also show strong association but only weak LD with the most strongly associated SNP (r 2 o 0.30). All loci with a P value o5 Â 10 À7 in our initial analysis were confirmed except for the association signal near GRIN3A. Supplementary Table 3 online provides stage 2 results for all SNPs, and Supplementary Table 4 online provides more detailed results for the SNPs highlighted in Table 3 .
Overall, we observed the strongest evidence for association (P o 10 À20 ) between HDL cholesterol and SNPs in CETP (rs3764261, rs1864163 and rs9989419; the three are in weak LD with each other), LIPC (rs4775041) and LPL (rs10503669); between LDL cholesterol and SNPs in the APOE-APOC cluster (rs4420638), near the CELSR2-PSRC1-SORT1 (rs599839), LDLR (rs6511720) and APOB (rs562338) genes; and between triglycerides and SNPs near the GCKR (rs780094), APOA5-APOA4-APOC3-APOA1 (rs12286037) and LPL (rs10503669) genes (P values and effect sizes are shown in Table 3 ). In each case, we observed strong evidence for association in both stages of genotyping (P o 5 Â 10 À7 ). The association of LDL cholesterol concentrations with the CELSR2-PSRC1-SORT1 locus is particularly notable, because variants in the region have not been previously implicated in lipid metabolism ( Supplementary Fig. 2c online). There is no obvious connection between the genes closest to the association signal, CELSR2 and PSRC1, and lipid metabolism. One possibility is that rs599839 or an associated variant influences expression of SORT1, a nearby gene that mediates endocytosis and degradation of lipoprotein lipase 32 . In our sample, allele A at rs599839 was associated with an increase of 5.48 mg/dl in LDL cholesterol concentrations. Notably, the same rs599839 allele has recently been associated with an increased risk of CAD in an independent study 33 , suggesting that the association to CAD risk might be mediated by the effect on LDL cholesterol concentrations.
Another tier of loci also remains significant after adjustment for 1,000,000 independent tests. This tier includes additional SNPs for loci within the previous tier and also SNPs near ABCA1, LIPC, LIPG and PCSK9 ( Table 3) . Of note, although polymorphisms in all of these genes have a well-established role in lipid metabolism, some of the Table 2 ). For example, in PCSK9, variants previously associated with LDL cholesterol concentrations have r 2 o 0.10 with the variants identified here (Supplementary Table 2 ). Other examples of newly identified risk alleles include LIPG (rs2156552), LIPC (rs4775041) and LDLR (rs6511720).
This tier also includes six loci where genetic variants have not previously been implicated in lipid metabolism. We found association between HDL cholesterol and SNPs near GALNT2 and near MVK and MMAB ( Supplementary Fig. 2a,b) ; between LDL cholesterol and triglycerides and SNPs in an extended region near NCAN and CILP2 ( Supplementary Fig. 2d,h) ; and between triglycerides and SNPs near TRIB1, MLXIPL and ANGPTL3 ( Supplementary Fig. 2e-g ). Among genes in these six regions, we observed the clearest connections to cholesterol and lipoprotein metabolism for MLXIPL, which encodes a protein that binds and activates specific motifs in the promoters of triglyceride synthesis genes, and for ANGPTL3, whose protein homolog is a major regulator of lipid metabolism in mice 34 . Rare variants in a related gene, ANGPTL4, have been associated with HDL and triglyceride concentrations in humans 35 . A connection to lipid metabolism has also been observed for MVK and MMAB, two neighboring genes that are regulated by SREBP2 and that share a common promoter 36 . MVK encodes mevalonate kinase, which catalyzes an early step in cholesterol biosynthesis, and MMAB encodes a protein that participates in a metabolic pathway that degrades cholesterol.
In the other three loci, we did not find any established connections to cholesterol metabolism. The signals near GALNT2 and TRIB1 each overlap a single gene. GALNT2 encodes a widely expressed glycosyltransferase that could potentially modify a lipoprotein or receptor. TRIB1 encodes a G-protein-coupled receptor-induced protein involved in the regulation of mitogen-activated protein kinases 37 and may regulate lipid metabolism through this pathway. In contrast, the association signal near NCAN extends for over 500 kb and encompasses 20 genes. In our combined data, rs16996148 (an Affymetrix array SNP near CILP2) was selected for follow-up and showed strong association with both LDL cholesterol (P B 2.7 Â 10 À9 ) and triglycerides (P B 2.5 Â 10 À9 ). The allele that is associated with increased LDL cholesterol concentrations is also associated with increased triglyceride concentrations, consistent with the modest positive correlation between the two traits but in contrast to other SNPs associated with both LDL cholesterol and triglycerides that showed association with only one of the traits in our sample. Notably, in the analysis of our three genome-wide association scans and imputed HapMap SNPs, a nonsynonymous coding SNP in the NCAN gene (rs2228603, Pro92Ser) showed the strongest evidence for association (P B 1.8 Â 10 À7 ). This SNP was not included in our initial follow-up analysis, which considered only SNPs on the Affymetrix arrays, but it was in strong LD with rs16996148 (r 2 ¼ 0.89). NCAN is a nervous system-specific proteoglycan involved in neuronal pattern formation, remodeling of neuronal networks and regulation of synaptic plasticity 38 , with no obvious relation to LDL cholesterol or triglyceride concentrations. 2) among these corroborating signals was calculated using LD information from the HapMap CEU sample. P values in bold exceed a threshold of 5 Â 10 À8 , which corresponds to a false-positive rate of 0.05 after adjustment for 1 million independent tests, comparable to the number of independent common SNPs in the Phase II CEU HapMap. For each locus, the most strongly associated SNP is indicated together with its position relative to nearby genes, with a focus on genes previously implicated in lipid metabolism. In the nearby gene column, positions are relative to the transcription start for the nearest gene.
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A final tier of genes has one or more SNPs with a P value o10 À5 when stage 1 and stage 2 data are considered together ( Table 3) . Among these genes is LCAT, which encodes a protein with a well-established role in lipid metabolism, and for which well-characterized, but rare, genetic variants have been shown to considerably affect lipid concentrations 39 . Our signal supports a single unconfirmed report of a common variant influencing HDL concentrations 40 . Two other association signals of note are located near the B3GALT4 and B4GALT4 genes. Similarly to GALNT2, these genes encode glycosyltransferases, and thus our results may The table summarizes association signals after follow-up of the promising SNPs in stage 2 samples. Column 1 headings are as described for Table 2 , with the addition of one-sided P values for the stage 2 samples, in which we tested for the same direction of effect as Stage 1-consistent with current best practice for replication of GWAS findings. The effect sizes shown were estimated from stage 2 samples only. SNPs with a combined (stage 1 + 2) P value o10 À5 were included, although we also show GRIN3A for completeness because it was significant in the initial scan. Rows corresponding to SNPs with a combined P value o 5 Â 10 8 are in boldface. SNPs in this table may not match those in Table 2 , which only displays the strongest signal in each locus. The discrepancy also reflects our bias towards genotyped Affymetrix 500K SNPs in the Stage 2 follow-up. Association P values for each of the six stage 2 samples are shown in Supplementary Table 4 .
implicate glycosyltransferases as having a previously unrecognized influence on variation in lipid concentrations: it is possible that they affect lipid concentrations by modifying lipoprotein receptors 41 . A summary of evidence for association between HDL cholesterol, LDL cholesterol and triglycerides and all markers genotyped or imputed in our initial survey of the genome is available online (see URLs section in Methods). This should enable other investigators to combine our results with their own data or to select SNPs for followup in other samples. As an example of the utility of this resource, in a companion report, Kathiresan and colleagues 16 used the DGI data and the meta-analysis resource to select a set of SNPs for examination in a sample of 418,000 individuals. They report convincing statistical evidence for six newly identified loci at P o 5 Â 10 À8 , all of which overlap with those in our study.
Association with coronary artery disease
In view of the well-established associations between lipid concentrations and CAD, we examined whether the alleles associated with lipid concentrations in the present study were also associated with CAD in the Wellcome Trust Case Control Consortium (WTCCC) sample of B2,000 CAD cases and an expanded reference panel of B13,000 British individuals 42 (including B3,000 random controls and B2,000 cases for each of five common diseases). Given the relatively modest changes in LDL cholesterol concentrations associated with the alleles we identified (changes of B2-9 mg/dl per allele), we expected that a subset of SNPs might also be associated with a small increase in susceptibility to CAD. Notably, the results show that all of the alleles that were associated with increased LDL cholesterol concentrations in our sample were more common among CAD cases than in the expanded reference panel ( Table 4) . Among eleven independent alleles (r 2 o 0.30 between nearby alleles) associated with increased LDL cholesterol concentrations in our sample (all with P o 10 À6 in our sample), all eleven showed increased frequency among CAD cases (P ¼ 2 À11 ¼ 0.0005). The increase was significant (P o 0.05) for eight of the SNPs, and nearly so (P o 0.06) for another two ( Table 4 , penultimate column). Although the associated risk estimates are small (relative risk increases of 1.04-1.29 per allele, see Table 4 ), it is extremely unlikely (P o 10 À11 ) that 10 of the 11 SNPs would show suggestive association with CAD at P o 0.06 by chance, making the connection between LDL and associated SNPs and CAD particularly worthy of note. Overall, although we observed a correlation between the strength of the observed association with CAD and the impact of each allele on LDL cholesterol concentrations (Spearman correlation coefficient r ¼ 0.71, P ¼ 0.015), we also found some alleles that had a strong association with LDL cholesterol but no significant association with CAD (for example, rs562338 in the APOB locus). We did not find a similar pattern of association for alleles associated with the other lipid traits (Supplementary Table 5 online), although alleles associated with increased triglyceride concentrations near TRIB1 (for example, at rs17321515) were also associated with increased risk of CAD (P ¼ 0.0008). Although the data suggest that nearly all alleles associated with increased LDL cholesterol concentrations will be associated with increased risk of CAD (given a large sample size), the converse is not true, as expected. Alleles at the chromosome 9 locus that show strong association with CAD, coronary heart disease and myocardial infarction 33, [42] [43] [44] do not seem to influence lipid concentrations in our sample (P ¼ 0.31 for association between LDL cholesterol and the SNP most strongly associated with CAD, rs1333049, in our stage 1, and P 4 0.50 for HDL cholesterol and triglycerides). Additional studies will show whether these variants are also associated with longevity 45 , stroke 46 and the other health outcomes associated with LDL cholesterol concentrations.
DISCUSSION
Genes at the loci implicated in our study affect the entire cycle of formation, activity and turnover of lipoproteins and triglycerides. Thus, they encode many of the apolipoproteins themselves (APOE, APOB and APOA5), but they also encode a transcription factor activating triglyceride synthesis (MLXIPL), an enzyme involved in cholesterol biosynthesis (MVK), transporters of cholesterol (ABCA1) and cholesterol ester (CETP), a lipoprotein receptor (LDLR), potential receptor-modifying glycosyltransferases (B4GALT4, B3GALT4 and GALNT2), lipases (LPL, LIPC and LIPG) and a protein involved in The table summarizes association between coronary artery disease and the alleles associated with LDL-C concentrations in our study. Evidence for association was evaluated in the Wellcome Trust Case Control Consortium panel and was not adjusted for additional covariates, because these are not available for the bulk of study participants. Rows corresponding to SNPs that show association with LDL cholesterol with P o 5 Â 10 À8 in our sample are in boldface.
cholesterol degradation (MMAB), an inhibitor of lipase (ANGPTL3) and a possible endocytic receptor for LPL (SORT1). Notably, some of the loci we identify (near TRIB1 and in the large region surrounding NCAN, for example) include no obvious functional candidates, and further studies to pinpoint the genes and mechanisms involved could lead to important new insights about lipid metabolism.
In multiple regression models, the variants identified here together accounted for only about 5-8% of the variation in the three lipid traits in the populations studied, leaving much of the heritability of these traits unexplained. The missing genetic factors might be accounted for by a much longer list of loci with common variants of small effect, by rare variants of large effect that have been missed by the association approach, or by interactions between these and other genetic and environmental factors. To clarify the overall role of the loci reported here, it will be critical to resequence the exons and conserved regions in a large number of individuals, in order to identify and evaluate all potential variants within each gene or cluster of genes. This resequencing effort will help identify the functional variants involved in each region. In addition, resequencing may identify nonsense, nonsynonymous or other changes that are associated with variability in lipid concentrations, clarifying the identity of the genes involved in regions with multiple candidates. Resequencing of certain candidate genes has shown that such rare variants can sometimes be identified in individuals at the extremes of lipid concentration distributions 47 ; thus, focused studies of the regions identified here in individuals with dyslipidaemia could be particularly informative.
Several of the loci newly identified in this report are potentially attractive drug targets. Furthermore, the ability to stratify individuals on the basis of specific genetic profiles may provide future benefits for optimization of therapy, given that lipid lowering drugs are already widely prescribed to help manage individual lipid profiles and reduce the risk of cardiovascular events 2 . For monogenic forms of diseases that lead to dysregulation of HDL cholesterol, LDL cholesterol or triglyceride concentrations, it is clear that individuals with different mutations require different therapeutic regimens 48, 49 . Thus, it is our hope that common variants at the loci identified here will lead to development of novel therapeutics and influence optimal treatment profiles for each individual, resulting in improved management of blood lipid concentrations and reduction of cardiovascular disease risk.
METHODS
Genome-wide association scans. We used standard protocols to genotype the Illumina 317K HumanHap 300 BeadChip and Affymetrix 500K and 10K Mapping Array Sets in the FUSION and SardiNIA samples, respectively. We collaborated with the authors of a previously published study 15 to integrate their results into our analysis. To facilitate comparison of results among the three studies, and to better assess the effects of unmeasured variants, we first identified stretches of haplotype shared between individuals in our sample and those in the HapMap CEU sample and then used these shared stretches to impute missing genotypes. This resulted in a total of B2,261,000 SNPs that were either genotyped or imputed with high confidence in all three samples.
Association analysis. We first analyzed each study independently. For each marker, we identified a reference allele and calculated statistics summarizing its evidence for association with HDL cholesterol, LDL cholesterol and triglycerides. Association models include gender, age and age 2 as covariates, and additional covariates appropriate to each study. These statistics were then combined across studies taking into account both the number of phenotyped individuals in each study and the direction and magnitude of the estimated effect.
Follow-up. SNPs from the loci showing the strongest evidence for association in the genome-wide scans were selected for analysis in follow-up samples. In our initial round of follow-up, we favored SNPs that were successfully genotyped in both the DGI and SardiNIA studies. As in the analysis of the initial scans, we first conducted analyses within each sample separately and then combined the resulting summary statistics by meta-analysis.
Coronary artery disease analysis. Individual genotype data for this analysis were obtained from the WTCCC website. We first imputed all relevant untyped SNPs using the HapMap CEU as a reference population and carried out tests for association with a likelihood-ratio test.
URLs. Association data, http://www.sph.umich.edu/csg/abecasis/public/ lipids/; Markov Chain Haplotyping Package, http://www.sph.umich.edu/csg/ abecasis/MaCH.
Note: Supplementary information is available on the Nature Genetics website.
